

## FIVE THINGS TO KNOW ABOUT ...

**Dextromethorphan abuse**

Tony Antoniou PhD, David N. Juurlink MD PhD

**Dextromethorphan is more than an innocuous antitussive**

At large doses used recreationally (300 to > 1500 mg), dextromethorphan and its metabolite dextrophan block *N*-methyl-D-aspartate receptors, producing dissociative effects similar to those of phencyclidine and ketamine.<sup>1</sup> Neurobehavioural effects can begin within one hour after ingestion, are dose-related and are described by users as occurring in “plateaus” (Box 1).<sup>2,3</sup> Adrenergic effects (e.g., hypertension, diaphoresis) can result from dose-related inhibition of catecholamine reuptake, and serotonergic effects can result from agonist effects at serotonin receptors.<sup>4</sup> Serotonin syndrome can also arise from interactions with serotonergic drugs.<sup>2,3</sup>

**Box 1: “Plateaus” of dextromethorphan toxicity\*<sup>2,3</sup>****Plateau 1 (1.5–2.5 mg/kg)**

- Total intake 100–200 mg (4–6 capsules or 35–60 mL of syrup)
- Restlessness, euphoria

**Plateau 2 (2.5–7.5 mg/kg)**

- Total dose 200–500 mg (7–18 capsules or 60–185 mL of syrup)
- Exaggerated auditory and visual sensations, closed-eye hallucinations, imbalance

**Plateau 3 (7.5–15 mg/kg)**

- Total dose 500–1000 mg (18–33 capsules or 185–375 mL of syrup)
- Visual and auditory disturbances, altered consciousness, delayed reaction times, mania, panic, partial dissociation

**Plateau 4 (> 15 mg/kg)**

- Total dose > 1000 mg (> 33 capsules or > 375 mL of syrup)
- Hallucinations, delusions, ataxia, complete dissociation

\*Assuming a 75-kg person, 30-mg capsules and 3 mg per millilitre of syrup.

**Clinical effects may be influenced by combined-formulation drugs**

Some effects attributed to dextromethorphan may reflect ingestion of combination drugs, particularly decongestants, acetaminophen and anticholinergic antihistamines.<sup>2,4</sup> Because dextromethorphan is not detected by basic drug screens, toxicity secondary to its use should be considered when evaluating patients with a dissociative toxidrome.<sup>2,4</sup>

**Treatment is supportive**

No specific antidote exists for dextromethorphan toxicity.<sup>3,5</sup> Guidelines suggest benzodiazepines for seizures and aggressive cooling measures for hyperthermia. Naloxone can be considered for use in patients in a coma or with respiratory depression, although clinical response is varied.<sup>2,4</sup> Acetaminophen levels should be obtained when concomitant ingestion is suspected, and additional measures for the management of associated complications (e.g., delayed hepatic injury related to acetaminophen overdose) implemented as appropriate.<sup>2,4</sup>

**Use is increasing among adolescents**

According to the Ontario Student Drug Use and Health Survey, 9.7% of students in grades 7 to 12 reported using dextromethorphan recreationally in 2013, compared with 6.9% in 2011.<sup>5</sup> Most dextromethorphan-related calls to poison control centres involve adolescent males and solid dose formulations of the drug.<sup>6</sup>

**Withdrawal can occur**

Anecdotal reports from long-term users (i.e., months to years) have described intense cravings, flashbacks and hallucinations within three days after stopping dextromethorphan.<sup>2,3</sup> Physical symptoms of withdrawal include diarrhea, vomiting and rigors. Symptoms typically resolve within two days without specific treatment.<sup>1</sup>

See references, Appendix 1, [www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.131676/-/DC1](http://www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.131676/-/DC1)

**Competing interests:** None declared.

This article has been peer reviewed.

**Affiliations:** Department of Family and Community Medicine (Antoniou), St. Michael's Hospital; Department of Family and Community Medicine (Antoniou), University of Toronto; Institute for Clinical Evaluative Sciences (Juurlink); Department of Medicine (Juurlink), Sunnybrook Health Sciences Centre, Toronto, Ont.

**Correspondence to:** Tony Antoniou, [tantoniou@smh.ca](mailto:tantoniou@smh.ca)

CMAJ 2014. DOI:10.1503/cmaj.131676